20 May 2020News UpdateNovalis Biotech Incubation to invest in CergentisNovalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount....Read more 16 March 2020News UpdateCOVID-19In light of the ongoing COVID-19 outbreak, we wish to briefly update you......Read more 6 January 2020News UpdateLaunch new websiteNew year, new website...Read more 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more 11 September 2019News UpdateCergentis on track with product development of TLA-based targeted complete next generation sequencing on FFPE samples for cancer diagnosticsBy combining proximity ligation with improved targeting strategies, we are able to sequence genes of interest completely, over a large width of 100’s of kilobas...Read more 31 August 2019News UpdateNew appnote releasedCergentis released a new application note: "Complete locus sequencing and quality control of targeted genome editing". ...Read more 9 April 2019News UpdateCergentis releases two new application notes: improving QC in cell & gene therapy manufacturing with TLAOur Targeted Locus Amplification (TLA) technology has unique advantages in the quality control of transgenic and genetically engineered samples. TLA can assess ...Read more 5 March 2019News UpdateCergentis’ TLA technology and Genedata software: efficient in-house data analysis for CHO cell line developmentTLA is used in multiple stages in CHO cell line development, e.g. early stage clone selection, and enables the assessment of genetic stability of Master Cell Ba...Read more
© 2012-2021 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.